Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
187actual
Sites
23
Countries
Austria, Israel, Switzerland +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-08-10 | actual | When the study began enrolling |
| Primary completion | 2026-01-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-30 | actual | The whole study's end, after follow-up |
| First posted | 2016-09-22 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma
- Herpetic Infection
Primary outcome
what the primary-completion date above is the date OFIncidence Rate
measured Up to 5 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed